Pulmonary Arterial Hypertension

ACCP Pulmonary Arterial Hypertension

ACCP GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/61602

Contents of this Issue

Navigation

Page 11 of 11

Strength of Recommendation A B C E Recommendation Grading Definition Strong recommendations Moderate recommendations Weak recommendations Recommendation based on expert opinion only Abbreviations 6MWD, 6-min walk distance; BMPR2, bone morphogenetic protein receptor type 2; CTEPH, chronic thromboembolic pulmonary hypertension; FC, functional class; HIV, human immunodeficiency virus; IPAH, idiopathic pulmonary arterial hypertension; LVEDP, leſt ventricular end diastolic pressure; μg, microgram; mPAP, mean pulmonary arterial pressure; ng, nanogram (109 arterial hypertension; PAP, pulmonary arterial pressure; PCWP, pulmonary capillary wedge pressure; PCH, pulmonary capillary hemangiomatosis; PDI, phosphodiesterase inhibitors; PH, pulmonary hypertension; PVOD, pulmonary venoocclusive disease; ULN, upper limit of normal; wks, weeks gram); NYHA, New York Heart Association; PAH, pulmonary Sources Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S43-54. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S55-66. Barst RJ, Gibbs JSR, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl): S78-84. Disclaimer This Guideline attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. This Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. The ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aſter consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. 5740 Executive Drive Suite 220 Baltimore, MD 21228 TEL: 410-869-3332 • FAX: 410-744-2150 For additional copies: orders@GuidelineCentral.com Copyright © 2011 All rights reserved

Articles in this issue

Links on this page

Archives of this issue

view archives of Pulmonary Arterial Hypertension - ACCP Pulmonary Arterial Hypertension